Intraocular implants for extended drug delivery: Therapeutic applications

被引:172
作者
Bourges, J. L.
Bloquel, C.
Thomas, A.
Froussart, F.
Bochot, A.
Azan, F.
Gurny, R.
BenEzra, D.
Behar-Cohen, F.
机构
[1] Univ Paris 05, U598, INSERM, F-75006 Paris, France
[2] Univ Paris 05, Sch Med, F-75006 Paris, France
[3] Hotel Dieu Paris Hosp, AP HP, F-75004 Paris, France
[4] Univ Paris Sud, Sch Pharm, CNRS, UMR 8612, F-92296 Chatenay Malabry, France
[5] Univ Geneva, Dept Biopharmaceut, Geneva, Switzerland
[6] Hadassah Hebrew Univ Hosp, Jerusalem, Israel
关键词
drug delivery; ocular implants; particulate drug delivery systems; nanoparticles; microparticles; polymers; liposomes;
D O I
10.1016/j.addr.2006.07.026
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
An overview of ocular implants with therapeutic application potentials is provided. Various types of implants can be used as slow release devices delivering locally the needed drug for an extended period of time. Thus, multiple periocular or intraocular injections of the drug can be circumvented and secondary complications minimized. The various compositions of polymers fulfilling specific delivery goals are described. Several of these implants are undergoing clinical trials while a few are already commercialized. Despite the paramount progress in design, safety and efficacy, the place of these implants in our clinical therapeutic arsenal remains limited. Miniaturization of the implants allowing for their direct injection without the need for a complicated surgery is a necessary development avenue. Particulate systems which can be engineered to target specifically certain cells or tissues are another promising alternative. For ocular diseases affecting the choroid and outer retina, transscleral or intrasscleral implants are gaining momentum. (c) 2006 Published by Elsevier B.V.
引用
收藏
页码:1182 / 1202
页数:21
相关论文
共 142 条
[1]
TREATMENT OF CYTOMEGALOVIRUS RETINITIS WITH INTRAVITREAL INJECTION OF LIPOSOME-ENCAPSULATED GANCICLOVIR IN A PATIENT WITH AIDS [J].
AKULA, SK ;
MA, PE ;
PEYMAN, GA ;
RAHIMY, MH ;
HYSLOP, NE ;
JANNEY, A ;
ASHTON, P .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1994, 78 (09) :677-680
[2]
CONTROL OF CYTOMEGALOVIRUS RETINITIS USING SUSTAINED-RELEASE OF INTRAOCULAR GANCICLOVIR [J].
ANAND, R ;
NIGHTINGALE, SD ;
FISH, RH ;
SMITH, TJ ;
ASHTON, P .
ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (02) :223-227
[3]
Andrieu-Soler C, 2005, MOL VIS, V11
[4]
INTRAVITREAL GANCICLOVIR PHARMACOKINETICS IN RABBITS AND MAN [J].
ASHTON, P ;
BROWN, JD ;
PEARSON, PA ;
BLANDFORD, DL ;
SMITH, TJ ;
ANAND, R ;
NIGHTINGALE, SD ;
SANBORN, GE .
JOURNAL OF OCULAR PHARMACOLOGY, 1992, 8 (04) :343-347
[5]
BARZA M, 1987, INVEST OPHTH VIS SCI, V28, P893
[6]
Development, implantation, in vivo elution, and retrieval of a biocompatible, sustained release subretinal drug delivery system [J].
Beeley, NRF ;
Stewart, JM ;
Tano, R ;
Lawin, LR ;
Chappa, RA ;
Qiu, GT ;
Anderson, AB ;
de Juan, E ;
Varner, SE .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A, 2006, 76A (04) :690-698
[7]
Bejjani R, 2005, MOL VIS, V11, P124
[8]
NEO-VASCULOGENIC ABILITY OF PROSTAGLANDINS, GROWTH-FACTORS, AND SYNTHETIC CHEMOATTRACTANTS [J].
BENEZRA, D .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1978, 86 (04) :455-461
[9]
INVIVO ANGIOGENIC ACTIVITY OF INTERLEUKINS [J].
BENEZRA, D ;
HEMO, I ;
MAFTZIR, G .
ARCHIVES OF OPHTHALMOLOGY, 1990, 108 (04) :573-576
[10]
BIOCOMPATIBILITY OF A NEW SEMISOLID BIOERODIBLE POLY(ORTHO ESTER) INTENDED FOR THE OCULAR DELIVERY OF 5-FLUOROURACIL [J].
BERNATCHEZ, SF ;
MERKLI, A ;
MINH, TL ;
TABATABAY, C ;
ANDERSON, JM ;
GURNY, R .
JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1994, 28 (09) :1037-1046